Neuropace Inc recorded a cumulative net loss of $-19 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 114 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3016, from total ranking in previous quarter at 3459.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NPCE Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-91,455	-103,182	-102,703	-114,766	-124,124
NPCE's Total Ranking	# 3016	# 3459	# 3141	# 3259	# 3240
Seq. Net Income Change	-	-	-	-	-

NPCE Company Profile >> Back to NPCE Efficiency Comparisons >> Compare NPCE Net Income per Employee to its Competitors

NPCE Net Income per Employee Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 115
Healthcare Sector	# 320
Overall Market	# 3016

Net Income per Employee Statistics
High	Average	Low
$ -42,153	$ -151,448	$ -225,273
(Mar 31 2021)		(Dec 31 2022)

News about Neuropace Inc Income per employee

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, Inc. - NPCE

Investigative Alert: Pomerantz Law Firm Probes Potential Investor Claims Against NeuroPace, Inc. Amidst Robust Revenue GrowthIn a notable development from the financial and legal landscapes, Pomerantz LLP is initiating an investigation concerning potential claims on behalf of investors of NeuroPace, Inc. (NASDAQ: NPCE). This action reflects the firm’s commitment to safeguarding the interests of investors navigating the dynamic sphere of biotechnology and medical technology firms, particularly in light of NeuroPace’s recent financial performance.NeuroPace has reported an impressive revenue uptick of 56.59% year-over-year, with a sequential revenue increase of 10.36%. These numbers indicate a robust growth trajectory for the company, highlighting its potential in a market that is increasingly becoming competitive. Such significant financial achievements could suggest that NeuroPace is well-positioned within the neuromodulation sector, particularly with its innovative therapies aimed at treating neurological disorders. Investors experiencing concerns regarding the integrity of their investments in NeuroPace are encouraged to reach out to Danielle Peyton at Pomerantz Law Firm for detailed consultations. By doing so, they can gain insight into their rights and the firm’s ongoing investigation, reflecting the larger trend of increased scrutiny in the health tech industry, where rapid growth often attracts both attention and concerns regarding operational transparency.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-09-04T10:33:25+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.